632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas

• Shuai Chen,
• Tianhong Li,
• Weijie Ma,
• Tingting Lu,
• Siqi Long,
• Kyra A Toomey,
• Michael Babich,
• Colleen Pineda,
• Laura Molnar,
• Leslie Garcia,
• Kit Tam,
• Rashmi Verma,
• Chihong Zhou,
• Nancy Ogilhara

Affiliations

Shuai Chen

4University of California, Davis, Sacramento, CA, USA

Tianhong Li

Aff98 grid.27860.3b0000000419369684University of California Davis Comprehensive Cancer Center Sacramento CA USA

Weijie Ma

3Dartmouth Health, Lebanon, NH, USA

Tingting Lu

2Zhuhai Yufan Biotechnologies Co., Ltd, GuangZhou, GuangDong Province, China

Siqi Long

3UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Kyra A Toomey

2UCDMC Comprehensive Cancer Center, Sacramento, CA, USA

Michael Babich

5LabyRx Immuno-Oncology, Sacramento, CA, USA

Colleen Pineda

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Laura Molnar

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Leslie Garcia

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Kit Tam

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Rashmi Verma

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Chihong Zhou

4UC Davis Health – Pathology, Sacramento, CA, USA

Nancy Ogilhara

1UC Davis Comprehensive Cancer Center, Sacramento, CA, USA